AML with BCR::ABL1 fusion still requires at least 20% blasts under both the WHO-HAEM5 and ICC, and no evidence of chronic myeloid leukemia (CML) can be established, while AML with CEBPA mutations requires ≥20% blasts by the WHO-HAEM5 but only >10% by the ICC. This evidence concerns the gene ABL1 and intrahepatic cholangiocarcinoma.